Search the Newsreel

3 Reasons We’re Fans of AAR (AIR)

3 Reasons We're Fans of AAR (AIR) AAR currently trades at $143.07 and has been a dream stock for shareholders. It's returned 315% since August 2021, blowing past the S&P 500's 73.6% gain. The company has also beaten the index over the past six …

AAR (AIR) Stock May Be Above Fair Value Following Its 320% Run

AAR (AIR) stock has seen a 320% return over the past five years, leading to questions about its current valuation. The stock trades at a P/E ratio of 30.0x, which is below the industry average but above Simply Wall St's fair P/E of 25.9x, …

Price to sales forward of Emaar, The Economic City – TADAWUL:4220

AIR Price History for AAR Corp Stock

This article from Barchart.com provides a price history for AAR Corp (AIR) stock, detailing features for members to access and analyze historical data, including daily prices, latest trades, and corporate actions. It also highlights 52-week key points, including high and low prices, Fibonacci levels, …

Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview

Aardvark Therapeutics, Inc. is projected to report a loss of 87 cents per share in its upcoming earnings. This information comes from a Refinitiv earnings preview. The full article content is accessible via TradingView, which provides news from various sources including Reuters.

Aarvi Encon Ltd. Earnings and Revenue – BSE:AARVI

Aarti Pharmalabs director Rajendra Gogri steps down

Form 8K STAAR Surgical Company For: 6 August By Investing.com

This article announces the filing of a Form 8K by STAAR Surgical Company on August 6th. The brief piece from Investing.com indicates that the Form 8K is publicly available for review. The publication also provides various market data and other news headlines.

Aardvark Therapeutics (AARD) Jumps 8.22% as Shares Push Toward Key Resistance at $8.29 - Anchored VWAP

Aardvark Therapeutics (AARD) Surges 8.22% to $7.9 as Bulls Defend Key Support - Smart Beta Flow

Xaar plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:XAARF) 2026-08-07

STAAR Surgical (NASDAQ: STAA) names Warren Foust chief executive

STAAR Surgical has appointed Warren Foust as President and Chief Executive Officer, effective August 4, 2026. Foust previously served as Interim Co-CEO, President, and COO, and his compensation package includes a base salary of $730,000, a significant cash bonus target, and substantial equity grants …

Aarvi Encon PAT surges 75% to ₹17.62 crore in FY26 on revenue growth

Aarvi Encon Q4 Results: Consolidated Net Profit Jumps 75.4% YoY to ₹1,762.05 lakhs

AAR Corp. (AIR) Hit a 52 Week High, Can the Run Continue?

Is STAAR Surgical (STAA) Undervalued After Naming A New CEO?

STAAR Surgical (STAA) recently appointed Warren Foust as its new CEO, drawing investor attention despite recent share price declines. While analysts set a consensus price target of $29.67, indicating the stock is undervalued, key risks such as reliance on a single distributor in China …

Staar Surgical (STAA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating an upward trend in its earnings estimates. This upgrade suggests positivity about its earnings outlook, which could lead to increased buying pressure and a rise in its stock price. The …

STAAR Surgical appoints Warren Foust as permanent CEO

STAAR Surgical has appointed Warren Foust as its permanent CEO, following a period of leadership uncertainty after the collapse of Alcon's $1.6 billion takeover bid. Foust, who previously served as interim co-CEO and president, will continue as president, while Deborah Andrews resumes her role …

STAAR Surgical (STAA) to Post Earnings on Wednesday

Aarti Surfactants’ Q1 FY27 profit nearly triples on strong revenue growth

Warren Foust Named President and CEO of STAAR Surgical, Deborah Andrews Transitions to Executive Vice President and CFO Roles

STAAR Surgical Company has appointed Warren Foust as its new President, Chief Executive Officer, and a board member, effective August 4, 2026. Foust previously served as interim co-CEO, president, and chief operating officer. Deborah Andrews, who served as interim co-CEO alongside Foust, will transition …

STAAR Surgical Reports More Than 4M Lenses Sold as CEO Changes

STAAR Surgical announced the appointment of Warren Foust as President and Chief Executive Officer, effective August 4, 2026, following an extensive global search. Foust, who previously served as Interim Co-CEO and President & Chief Operating Officer, will focus on revenue growth, profit expansion, and …

STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO

STAAR Surgical Company has appointed Warren Foust as President and CEO, and a new member of its Board of Directors, effective immediately. Deborah Andrews, who served as Interim Co-CEO alongside Foust, will now serve as Executive Vice President while continuing her role as Chief …

STAAR Surgical to discuss vision correction business Aug. 12

STAAR Surgical (NASDAQ: STAA) announced it will release its second-quarter 2026 financial results and a shareholder letter on August 12, 2026, after market close. The company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial performance, operational …

AAR CORP SEC Filing (Aug 4, 2026)

This article reports on an SEC filing by AAR CORP (AIR) on August 4, 2026, which is categorized as a "DEF 14A" Definitive Proxy Statement. The filing has a "Low" impact and "Neutral" sentiment according to Rhea-AI. The article also provides an overview of …

STAAR Surgical Company Revenue Breakdown – NASDAQ:STAA

This article provides a breakdown of STAAR Surgical Company's (NASDAQ: STAA) revenue. Last year, the company generated $239.44 million USD, with its top-performing segment, Non-consignment, contributing $178.99 million USD. The "Other" segment accounted for $93.84 million USD last year.

AAR Corp stock hits all-time high at 146.99 USD By Investing.com

AAR Corp's stock has reached an all-time high of $146.99, reflecting a 97.6% one-year change and nearly 73% year-to-date returns. This surge is supported by 19% revenue growth over the last twelve months and a $5.63 billion market capitalization. Despite being deemed overvalued by …

Janus Henderson Group PLC Has $19.30 Million Holdings in AAR Corp. $AIR

Janus Henderson Group PLC reduced its stake in AAR Corp. by 5.9% in the first quarter, now holding 176,327 shares valued at $19.3 million, while institutional investors collectively own 90.74% of the company. AAR Corp. has a consensus "Moderate Buy" rating from analysts with …

AAR CORP (AIR) SVP sees 6,663 shares withheld to cover tax obligations

Jessica A. Garascia, Senior VP, GC, CAO & Secretary of AAR CORP (AIR), had 6,663 shares withheld on July 31, 2026, to cover tax obligations related to the vesting of performance-based and time-based restricted stock. The shares were withheld at a price of $140.04 …

Edgestream Partners L.P. Invests $1.42 Million in AAR Corp. $AIR

Edgestream Partners L.P. has acquired a new stake of 12,945 shares in AAR Corp., valued at approximately $1.42 million. This move is part of broader institutional investor activity, with various hedge funds modifying their holdings in AAR. Analysts maintain a "Moderate Buy" rating for …

AAR CORP (NYSE: AIR) SVP has 8,392 shares withheld to cover tax bill

Christopher A. Jessup, Senior Vice President-CCO of AAR CORP (NYSE: AIR), reported that 8,392 shares of common stock were withheld on July 31, 2026, to cover tax withholding obligations. These obligations arose from the vesting of performance-based and time-based restricted stock awards, with the …

Earnings Flash (XAR.L) Xaar plc Posts H1 Loss GBX-2.3

Xaar plc (XAR) Reports 9.2% Revenue Growth to £29.7 Million and Returns to Adjusted Profit in H1 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Hold" by Brokerages

Aarti Surfactants Ltd. Share Price Today: 11.39% Increase

Aarti Drugs uploads Q1FY27 earnings call audio, transcript to follow